Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ClearPoint Neuro, Inc. (Nasdaq: CLPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ClearPoint Neuro is a medical device company that develops device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine, and its filings offer detailed insight into this business.
Here you can review current and historical Forms 8-K, which ClearPoint Neuro uses to report material events such as preliminary unaudited financial results and significant transactions. For example, the company has filed 8-Ks announcing quarterly and annual financial results, as well as the completion of its acquisition of IRRAS Holdings, Inc., a transaction that expands ClearPoint Neuro’s presence in intracranial fluid management and neurocritical care.
Investors can also use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on revenue by category, operating expenses, and risk factors relevant to ClearPoint Neuro’s neurosurgical navigation, laser therapy, biologics and drug delivery, and intracranial fluid management activities. In addition, registration statements and related documents may describe share issuances connected to mergers or financing arrangements, such as the common stock issued in connection with the IRRAS merger.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new CLPT filings, including Forms 4 for insider transactions and proxy materials related to governance and compensation, are available as they are posted. This page is intended as a central resource for analyzing ClearPoint Neuro’s regulatory history, capital structure changes, and material corporate events through its official SEC filings.
ClearPoint Neuro, Inc. Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 1,729,611 shares of Common Stock, representing 6.1% of the class as of
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity involving restricted stock units. On March 11, 2026, 4,145 restricted stock units settled into the same number of common shares at a stated price of $0.00 per share, reflecting non-cash vesting.
In connection with this vesting, 2,109 common shares were delivered back to ClearPoint Neuro at $11.62 per share to satisfy tax withholding obligations, not as an open-market sale. After these transactions, D’Alessandro directly held 86,658 shares of common stock.
ClearPoint Neuro Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares. He exercised 8,291 restricted stock units into 8,291 shares of common stock. Of these, 3,224 shares at
ClearPoint Neuro CEO Joseph Burnett reported routine equity compensation activity. On March 6, 2026, 47,407 restricted stock units converted into the same number of shares of common stock at a stated price of $0.00 per share, reflecting scheduled vesting.
To cover tax obligations from this vesting, 22,709 common shares were delivered back to ClearPoint Neuro at $10.00 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Burnett directly holds 54,232 common shares and indirectly holds 193,231 common shares through the Joseph M. Burnett Trust dated October 20, 2022.
ClearPoint Neuro Chief Business Officer Jeremy L. Stigall settled previously granted equity awards into common shares and had part withheld for taxes. On
To cover tax obligations tied to this vesting, 6,913 common shares were delivered back to ClearPoint Neuro at
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin settled previously granted restricted stock units into 13,827 shares of common stock on their scheduled vesting date. To cover tax withholding obligations, 7,036 shares were delivered back to ClearPoint Neuro. Following these compensation-related transactions, Mazin directly holds 54,523 shares of common stock.
ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity. He exercised 18,765 restricted stock units, converting them into the same number of common shares at a stated price of
To cover tax obligations from this vesting, 9,548 common shares were delivered back to ClearPoint Neuro at
ClearPoint Neuro, Inc. director and CEO Joseph Burnett settled restricted stock units into common shares on
To cover tax withholding obligations tied to this vesting, 9,533 common shares were delivered to ClearPoint Neuro at
ClearPoint Neuro, Inc. Chief Financial Officer Danilo D'Alessandro reported equity award activity. On March 3, 2026, he exercised 10,332 Restricted Stock Units, converting them into 10,332 shares of common stock, as part of a scheduled vesting. Following this, his directly held common stock position was 75,405 shares, and his remaining directly held Restricted Stock Units totaled 41,328 units. To cover tax withholding tied to the vesting, 5,257 shares of common stock were delivered to ClearPoint Neuro at a price of
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall reported vesting of 8,856 restricted stock units, which were settled into an equal number of shares of common stock at a stated price of
In connection with this vesting, 4,506 shares of common stock were delivered to ClearPoint Neuro at